Navigation Links
Men taking long-acting chronic pain meds 5xs more likely to have low testosterone levels
Date:1/31/2013

OAKLAND, Calif., January 31, 2013 Low testosterone levels occur five times more often among men who take long-acting instead of short-acting opioids for chronic pain, according to a new Kaiser Permanente study published in The Clinical Journal of Pain.

While it has been known that opioids cause low testosterone in men, this study is the first to show a significant difference in risk between short-acting (immediate release) and long-acting opioids.

The 81 men in the retrospective study were between 26 and 79 years old (median age 51) and were seen in the chronic-pain clinic at Kaiser Permanente's Santa Rosa Medical Center (Calif.) between January 2009 and June 2010. All of the participants had been on a stable dose of an opioid for at least three months, and none had a previous diagnosis of low testosterone. A larger retrospective study of more than 1,500 male pain patients is currently under way.

"There's a large gap in the evidence base with regard to opioids," said Andrea Rubinstein, MD, of the Departments of Chronic Pain and Anesthesiology, Kaiser Permanente Santa Rosa Medical Center. "More safety and efficacy studies are needed. We need to know how we can prescribe these very useful medications in a way that brings the greatest benefits to our patients, without introducing additional risks."

Once prescribed primarily to cancer patients, the use of opioid-based medications such as oxycodone (Oxycontin) and hydrocodone (Vicodin) for treating chronic, non-cancer pain has increased dramatically in recent decades. An estimated 4.3 million Americans use opioids on a daily basis for pain.

"For years, doctors have been encouraged to prescribe long-acting opioids rather than short-acting opioids because we believed they were safer, had less abuse potential, and offered more consistent pain control, but no study has ever been able to support this practice," Dr. Rubinstein said.

The study compared the use of short-acting opioids, which immediately release the pain medication and are taken every four to six hours, and long-acting opioids, which slowly release the pain medication and are taken every eight to 12 hours.

A healthy young man should have testosterone levels between 300 and 800 nanograms per deciliter (ng/dL); in this study, low testosterone, also known as hypogonadism, was defined as less than 250 ng/dL. Low testosterone levels have been associated with decreases in muscle mass, bone density (osteoporosis or osteopenia), cognition, mood, libido (sex drive) and general quality of life.

Seventy-four percent of the men on long-acting opioids had low testosterone levels, compared with 34 percent of the men using short-acting opioids. After controlling for daily dosage and body mass index, the study found that the odds of having low testosterone were 4.78 times greater for men taking a long-acting opioid than a short-acting opioid. Dose was not associated with an increased risk of low testosterone.

"These medications work well for short-term, acute pain," said Dr. Rubinstein. "It has long been extrapolated that they can also be used safely long-term to control chronic pain. We are now finding that the long-term use of opioids may have important unintended health consequences."


'/>"/>

Contact: Vincent Staupe
vstaupe@golinharris.com
415-318-4386
Kaiser Permanente
Source:Eurekalert

Related medicine news :

1. The US Drug Watchdog Now Urges Young Women Who Suffered a Heart Attack or Blood Clotting After Taking Yaz or Yasmin Birth Control Pills to Contact the Johnson Law Group
2. Eat Too Much While Watching TV? Try Taking Smaller Bites
3. Why good resolutions about taking up a physical activity can be hard to keep
4. Mistaking OCD for ADHD has serious consequences
5. Gen X overtaking baby boomers on obesity
6. Millions May Be Taking Vitamin D Unnecessarily, Analysis Suggests
7. Year of Taking Risky Blood Thinners May Be Unnecessary After Stent Surgery
8. Taking Breaks From Prostate Cancer Hormone Therapy Seems Safe: Study
9. Children taking steroids for asthma are slightly shorter than peers
10. Many Teens Drinking, Taking Drugs During School: Survey
11. More Kids Taking Antipsychotics for ADHD: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 23, 2017 , ... Texas Home Health, an ... two personal care service companies: Padre Home Health in Corpus Christi, Texas, and ... , Well regarded in their respective markets, these two agencies align with Texas ...
(Date:1/24/2017)... Clara, CA (PRWEB) , ... January 23, 2017 ... ... announces the launch of a new plugin that allows sleep centers to automatically ... Sleep Device Interface (SDI)—is a thin client browser plugin is quickly installed on ...
(Date:1/23/2017)... ... January 23, 2017 , ... PKF O’Connor Davies ... J. Nelson, a senior accountant at the Firm, will participate in the 40th Annual ... Over 200 runners will race up 1,576 steps, a vertical distance equal to about ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... the highly acclaimed series, Innovations with Ed Begley, Jr., scheduled to broadcast Saturday, ... technology behind SmartCap, which was founded in 2008 to address the limitations of ...
(Date:1/23/2017)... ... January 23, 2017 , ... The Masters ... management and evaluation leaders with decades of experience who remain current practitioners in ... States healthcare system, there is a renewed demand for versatile, data-driven leadership.The American ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... The global peripheral I.V. catheter market accounted for $3,702.2 ... grow at a CAGR of 6.0% during 2016-2022. The ... in the global market between the two types in ... segment accounted for the highest share in the global ... catheter market is witnessing high growth rate, due to ...
(Date:1/24/2017)... CHICAGO , January 23, 2017 ... solutions for life sciences, announces agClinical 3.3, the latest ... release further enables life science organizations to confidently and ... monitoring and better manage the electronic trial master file ... ...
(Date:1/23/2017)... , Jan. 23, 2017  HOPE BIOSCIENCES announced ... to develop and commercialize nuc -gemcitabine™ (APTA-12/HOPE-888) ... Korean pharmaceutical company. nuc -Gemcitabine ... against surface nucleolin found on many cancer cells, ... ADCs (antibody drug conjugates) or SMDCs (small molecule ...
Breaking Medicine Technology: